$10 a Week Becomes $1,100: the Canadian Pharmacy Cutoff Arrives in Late October
Millions of Americans fill prescriptions through foreign mail-order pharmacies, and a customs rule taking full effect Oct. 22 could cut that supply off. One Dallas patient’s Xifaxan goes from about $10 a week to $1,100; here’s how to line up domestic fallbacks now.
By Sean Anees Saifi · Capital Wealth · Published Friday, September 25, 2026 · Source: The Wall Street Journal, Wednesday, September 23, 2026 edition, whose market figures are the Tuesday, September 22 close
Key Points
Starting Oct. 22, medications mailed from abroad must go through a formal customs entry, with a licensed customs broker and a party financially on the hook if a shipment doesn’t qualify — something individual mail-order refills have almost never needed, the Journal reports.
Millions of Americans buy everyday prescriptions by mail from pharmacies abroad, most of them in Canada, the Journal reports — and many are scrambling to stock up before the deadline.
The human arithmetic: one Texas patient has paid about $10 a week for Xifaxan, a gut-condition drug her U.S. insurer wouldn’t cover. After the cutoff she faces $1,100 a week. “I’m extremely upset,” she told the paper.
Supply may dry up before the rule bites: Northwest Pharmacy, a British Columbia drugstore, said it can’t promise delivery on orders placed after Oct. 9 and has stopped restocking. The rule covers FDA-regulated mail from any country, not just Canada.
~$10
weekly cost via the Canadian pharmacy
$1,100
weekly cost after the loophole closes
110x
the multiple — same pill, different paperwork
Oct. 22
the day the customs gap fully closes
For decades, mailed prescriptions were barred on paper and waved through in practice. After Oct. 22, someone has to answer for each package.
In one line: A customs rule, not a price change, is about to multiply one patient’s drug bill 110-fold on a deadline — which is why medication costs belong in the plan with a stress case.
The cruelest numbers in Wednesday’s paper have nothing to do with the bond market. A Texas woman with a painful gut condition has spent two years buying Xifaxan through a Canadian pharmacy for about $10 a week — her U.S. insurer wouldn’t cover it, and buying it at home would cost her $1,100 a week. On Oct. 22, the personal-importation loophole she uses closes: mailed medications will need a formal customs entry — a licensed broker, plus someone financially on the hook if a package doesn’t qualify — a hurdle an individual’s refill has almost never had to clear. She is one of millions of Americans who buy this way, the Journal reports, and many are now racing the calendar to stock up.
Notice what the rule doesn’t do: it doesn’t ban the drug or change its price. It ends a tolerance — for decades these imports were off-limits on paper but, importers say, seldom policed — and in practice leaves Zonos, a Utah company that processes customs paperwork for much of this mail, checking each package against the FDA’s criteria. A reminder that in American healthcare, the plumbing is the policy. And the savings at stake aren’t always 110-fold: a 90-day supply of the blood thinner Eliquis from Canada runs under $600, the paper notes, about half the U.S. retail price on domestic discount platforms. Plenty of households that budget carefully for groceries couldn’t say what their medications will cost in 90 days, because the answer can change with a customs rule.
Our read
If anyone in your household fills prescriptions from abroad, the calendar is shorter than it looks: the gap closes Oct. 22, and at least one Canadian pharmacy already can’t promise delivery on orders placed after Oct. 9, so the cheap supply may dry up first. Because these imports were never formally allowed, the durable fix is domestic, so start now: ask the prescriber about alternatives and therapeutic substitutes, and price the domestic options in parallel — manufacturer copay and patient-assistance programs, prescription discount cards, low-cost U.S. mail-order generics. Some can beat what insurance charges. Appeal the insurer’s coverage denial in writing, too; a denial isn’t always the last word.
For the plan itself (M5, cash flow): medication costs belong in the budget as a line item with a stress case, exactly like the heating-oil bill in this edition’s diesel story. A drug that’s affordable today and double — or 110 times — the price after a policy change isn’t a hypothetical anymore; it’s this October. The households that handle it best will be the ones that spent an hour on it in September.
What It Means For Your Portfolio
Hold — a budget deadline, not a market event
No portfolio action. This is a cash-flow deadline with a date on it — Oct. 22, and the cheap supply may run out sooner: talk to the prescriber now, then price the domestic fallbacks — assistance programs, discount cards, U.S. mail-order generics — before the first full-price refill arrives.
General planning principles, not advice for anyone in particular. Healthcare inflation doesn’t arrive evenly; it arrives as cliffs — a formulary change, a policy memo, a turned-65 birthday. The defense is procedural: know every medication’s true cash price, its generic, and its assistance program before you need them.
For anyone on Medicare, this is also a Part D note: drug-plan choices can be changed each year, formularies differ widely, and manufacturer copay coupons generally can’t be used with Part D coverage. Medicare’s open enrollment runs Oct. 15 to Dec. 7 — the stretch of the year when this paperwork actually pays.
